A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

INCLUSION:

* Bidimensionally measurable current/refractory aggressive NHL (Diffuse lg cell, diffuse mixed cell, follicular lg non-cleaved, immunoblastic, Ki-1+ALCL, peripheral T-cell lymphoma, mantle cell lymphoma \& transformed lymphoma.)
* No more than 3 prior treatment regimens. No anti-lymphoma therapy within the past 3 weeks.
* Not be eligible for treatment of a higher priority.
* Performance status \<2 Zubrod, \> 60 Karnofsky.
* Good marrow reserve: ANC\>1.5 x 10(9)/L, platelets \> 100 x 10(9)/L.
* Bilirubin \<1.5mg/dL, SGOT, SGPT \< 2 x normal values.
* Serum creatinine \< 1.8 mg/dL.
* Age \> 18 yrs.
* Signed informed consent.
* Life expectancy of \> 12 weeks.
* No prior Taxane (paclitaxel or docetaxel), topotecan, or CPT-11.
* No prior stem cell or bone marrow transplantation.
* No prior second malignancies except for basal cell carcinoma of the skin.

EXCLUSION:

* Active or prior history of CNS lymphoma.
* Serious intercurrent medical illnesses requiring hospitalization.
* History of primary/secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on a functional immune system) or patients taking immunosuppressive drugs (systemic corticosteroids).
* Prior exposure to Filgrastim-SD/01.
* Women who are pregnant or lactating.
* Participation in another clinical trial.
* Positive HIV antibody.
* History of prior sensitivity to E. coli derived products (such as filgrastim/neupogen).